Rua Bioscience Ltd.

As of June 30, 2024, Rua Bioscience Ltd. carries a market capitalization of 7.36M, placing it among publicly traded companies globally. Its enterprise value stands at 6.61M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2024, Rua Bioscience Ltd. has 188.80M shares outstanding.

These figures are as of June 30, 2024. The price-to-sales ratio is 84.89, and the price-to-book ratio stands at 1.09.

These figures are as of June 30, 2024. The EV/Sales ratio of 76.98 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 6.61M versus a market cap of 7.36M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2024, Rua Bioscience Ltd. maintains a current ratio of 3.22, meaning it holds 3.2x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2024, Rua Bioscience Ltd. posted a negative return on equity (ROE) of -102.05, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -95.63, reflecting losses generated across the asset base. Inventory turnover of 1.40 indicates how many times Rua Bioscience Ltd. sells and replaces its inventory over a year, a key working capital efficiency ratio.

As of the close on October 22, 2026, Rua Bioscience Ltd.'s stock has declined approximately 29.05% over the past 52 weeks. The 50-day moving average sits at 0.03, while the 200-day moving average is 0.03.

Over the twelve months ended June 30, 2024, Rua Bioscience Ltd. generated 85,837.00 in revenue and converted that into -13.72M in net income, yielding earnings per share of -0.07. EBITDA reached -14.06M, while operating income came in at -5.25M.

As of June 30, 2024, Rua Bioscience Ltd. holds 895,131.00 in cash and equivalents against 147,780.00 in total debt, resulting in a net debt position of -895,131.00. Total book value stands at 6.77M, with working capital of 1.94M providing operational flexibility.

These figures cover the twelve months ended June 30, 2024.

Over the twelve months ended June 30, 2024, Rua Bioscience Ltd. posted a gross margin of -137.83, reflecting its pricing power and cost economics. The operating margin of -6,115.07 and net profit margin of -15,982.33 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2024. Total shareholder yield reaches 1.29, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Rua Bioscience Ltd. shareholders.

Rua Bioscience Ltd.'s most recent stock split took place on September 28, 2026 with a 28:29 split ratio.

As of June 30, 2024, Rua Bioscience Ltd. has an Altman Z-Score of -7.62, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.